A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy.
B-cell depletion therapy
lupus nephritis
rituximab
systemic lupus erythematosus
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
27
12
2020
accepted:
18
01
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of care in biopsy-proven lupus nephritis (LN). Thirty patients were administered an IBCDT (4 weekly rituximab [RTX] 375 mg/m At 12 months, complete renal remission was observed in 93% of patients on IBCDT, in 62.7% on MMF, and in 75% on CYC ( In biopsy-proven LN, the IBCDT without further immunosuppressive maintenance therapy was shown to be as effective as conventional regimen of MMF or CYC followed by >3-year maintenance either MMF or AZA regimen. Moreover, the use of IBCDT was associated with a marked reduction of glucocorticoid cumulative dose.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of care in biopsy-proven lupus nephritis (LN).
METHODS
METHODS
Thirty patients were administered an IBCDT (4 weekly rituximab [RTX] 375 mg/m
RESULTS
RESULTS
At 12 months, complete renal remission was observed in 93% of patients on IBCDT, in 62.7% on MMF, and in 75% on CYC (
CONCLUSION
CONCLUSIONS
In biopsy-proven LN, the IBCDT without further immunosuppressive maintenance therapy was shown to be as effective as conventional regimen of MMF or CYC followed by >3-year maintenance either MMF or AZA regimen. Moreover, the use of IBCDT was associated with a marked reduction of glucocorticoid cumulative dose.
Identifiants
pubmed: 33912758
doi: 10.1016/j.ekir.2021.01.027
pii: S2468-0249(21)00030-9
pmc: PMC8071649
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1081-1087Informations de copyright
© 2021 International Society of Nephrology. Published by Elsevier Inc.
Références
Kidney Int. 2019 Feb;95(2):281-295
pubmed: 30665569
Arthritis Rheum. 2006 Aug;54(8):2550-7
pubmed: 16868977
Arthritis Rheum. 2013 Aug;65(8):2154-60
pubmed: 23754671
Ann Rheum Dis. 2012 Nov;71(11):1771-82
pubmed: 22851469
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1502-1509
pubmed: 30089664
Ann Rheum Dis. 2020 Jun;79(6):713-723
pubmed: 32220834
Immunol Rev. 2010 Sep;237(1):264-83
pubmed: 20727041
Medicine (Baltimore). 2003 Sep;82(5):299-308
pubmed: 14530779
Ann Rheum Dis. 2018 Sep;77(9):1318-1325
pubmed: 29730634
J Am Soc Nephrol. 2004 Feb;15(2):241-50
pubmed: 14747370
Autoimmun Rev. 2015 Dec;14(12):1123-30
pubmed: 26244817
Autoimmun Rev. 2019 Dec;18(12):102406
pubmed: 31654743
Arthritis Rheum. 2011 Dec;63(12):3918-30
pubmed: 22127708
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
Arthritis Care Res (Hoboken). 2010 Jun;62(6):873-80
pubmed: 20191478
Arthritis Rheumatol. 2016 Jun;68(6):1432-41
pubmed: 26815601
Arthritis Rheum. 2012 Apr;64(4):1215-26
pubmed: 22231479
J Invest Dermatol. 2009 Feb;129(2):278-88
pubmed: 19148217
Nephrol Dial Transplant. 2011 Dec;26(12):3987-92
pubmed: 21385860
Ann Rheum Dis. 2013 Aug;72(8):1280-6
pubmed: 23740227